Natera 2026 UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning, everybody. Thank you for joining us. On behalf of UBS, first off, I'm Doug Schenkel, just in case you don't know, and it's my pleasure on behalf of UBS to welcome Mike Brophy, CFO of Natera. Michael, thank you for being here.
Oh, thanks for having me. Good to see you guys.
Looking around the room, I think most of you know Natera, but I think it's important to just set the stage by acknowledging the journey you've been on, where you guys have just done a remarkable job establishing a leadership position in reproductive health, and then moving into MRD. I mean, there's not too many companies where you say, at least in our space, you did a really good job in one area, and then you go out and dominate with a second act. You guys have done that in MRD, a market we believe could ultimately represent a $15 billion-$30 billion annual revenue opportunity. You're now pursuing additional indications, adjacencies, and moving into new geographies. We'll tackle a little bit of that today.
With that in mind, before we get into it, just to provide a roadmap, there were a few developments last week at the company.
Panorama volumes? Panorama volumes is where we are going to start.
But I definitely want to talk about the CEO announcement, the 2029 framework.
Yeah. Then we will get into the all-important questions about Signatera, adjacencies, geographies, and CRC screening.
We will see what we can cover over the next half hour. Kicking off on the CEO transition.
Yeah. Maybe tell us about Solomon before we break down how we got here.
Yeah. Solomon is the 40th or 41st employee that joined Natera in 2011. There's probably not one single person that's more responsible for the development of these additional areas of focus, first with Prospera in organ health, and then ultimately with Signatera, making the critical choices around what clinical questions to answer, what clinical trials to run, which KOLs to partner with, every decision around product and product strategy for Signatera. Solomon was really the point person for all of that and is obviously critical in the commercial rollout for Signatera. It was a pleasure to listen to Bhavna do the intro for the conference and to have her mention MRD as an industry vertical.
Doug and I have done these conferences over the last decade where MRD did not exist as an industry vertical. I'm up here trying to convince people that it ought to be, that this ought to work. It's a pleasure to hear it just mentioned as, of course, it's one of these things that are common and rapidly emerging as a standard of care. Solomon's had a huge role in that. He's worked in each kind of area of the business. He's deeply connected to our R&D teams and our sales teams. I think Natera's a little bit unique in the structure of our leadership team in that we've got a bunch of really long-tenured executives. You mentioned my journey. I've been here 11 years, and I'm the newcomer.
Yeah You take a picture of me around 2011 when I first met the company, if you'd taken a picture of us at that first meeting and taken a picture of us at our board meeting this week, it's really all the same people.
It's really the same folks, the same core technology, and it's really the same core strategy. We're just a little bit further along. There's a lot of continuity in the handoff between Steve and Solomon. Another thing that's made it a little bit unusual about us is, we're all really dear friends. I know Steve's excited for Solomon. I'm excited for Solomon, and we know he's ready.
Why so abrupt? At least from the outside, it seems like this came out of nowhere.
How'd this happen? Yeah, no, I understand from the outside it can be perceived that way.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
